Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 9207 | 2021 |
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex KV Lu, JP Chang, CA Parachoniak, MM Pandika, MK Aghi, D Meyronet, ... Cancer cell 22 (1), 21-35, 2012 | 553 | 2012 |
Hypoxia-Induced Autophagy Promotes Tumor Cell Survival and Adaptation to Antiangiogenic Treatment in GlioblastomaAutophagy Mediates Resistance to Antiangiogenic Therapy YL Hu, M DeLay, A Jahangiri, AM Molinaro, SD Rose, WS Carbonell, ... Cancer research 72 (7), 1773-1783, 2012 | 472 | 2012 |
Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation MK Aghi, BS Carter, GR Cosgrove, RG Ojemann, S Amin-Hanjani, ... Neurosurgery 64 (1), 56-60, 2009 | 442 | 2009 |
Impact of extent of resection for recurrent glioblastoma on overall survival O Bloch, SJ Han, S Cha, MZ Sun, MK Aghi, MW McDermott, MS Berger, ... Journal of neurosurgery 117 (6), 1032-1038, 2012 | 436 | 2012 |
Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment S Müller, G Kohanbash, SJ Liu, B Alvarado, D Carrera, A Bhaduri, ... Genome biology 18, 1-14, 2017 | 415 | 2017 |
Oncolytic viral therapies–the clinical experience M Aghi, RL Martuza Oncogene 24 (52), 7802-7816, 2005 | 373 | 2005 |
Human glioblastoma–derived cancer stem cells: Establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors H Wakimoto, S Kesari, CJ Farrell, WT Curry Jr, C Zaupa, M Aghi, T Kuroda, ... Cancer research 69 (8), 3472-3481, 2009 | 368 | 2009 |
Prodrug activation enzymes in cancer gene therapy M Aghi, F Hochberg, XO Breakefield The journal of gene medicine 2 (3), 148-164, 2000 | 260 | 2000 |
Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group MA Vogelbaum, S Jost, MK Aghi, AB Heimberger, JH Sampson, PY Wen, ... Neurosurgery 70 (1), 234-244, 2012 | 240 | 2012 |
Biology of angiogenesis and invasion in glioma MC Tate, MK Aghi Neurotherapeutics 6 (3), 447-457, 2009 | 238 | 2009 |
Association of maximal extent of resection of contrast-enhanced and non–contrast-enhanced tumor with survival within molecular subgroups of patients with newly diagnosed … AM Molinaro, S Hervey-Jumper, RA Morshed, J Young, SJ Han, ... JAMA oncology 6 (4), 495-503, 2020 | 236 | 2020 |
Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes M Aghi, KS Cohen, RJ Klein, DT Scadden, EA Chiocca Cancer research 66 (18), 9054-9064, 2006 | 225 | 2006 |
Gene Expression Profile Identifies Tyrosine Kinase c-Met as a Targetable Mediator of Antiangiogenic Therapy Resistancec-Met Mediates Antiangiogenic Therapy Resistance A Jahangiri, M De Lay, LM Miller, WS Carbonell, YL Hu, K Lu, MW Tom, ... Clinical Cancer Research 19 (7), 1773-1783, 2013 | 210 | 2013 |
Tumor cell autophagy as an adaptive response mediating resistance to treatments such as antiangiogenic therapy YL Hu, A Jahangiri, M DeLay, MK Aghi Cancer research 72 (17), 4294-4299, 2012 | 208 | 2012 |
Heat-shock protein peptide complex–96 vaccination for recurrent glioblastoma: a phase II, single-arm trial O Bloch, CA Crane, Y Fuks, R Kaur, MK Aghi, MS Berger, NA Butowski, ... Neuro-oncology 16 (2), 274-279, 2014 | 196 | 2014 |
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging RF Barajas Jr, JJ Phillips, R Parvataneni, A Molinaro, E Essock-Burns, ... Neuro-oncology 14 (7), 942-954, 2012 | 194 | 2012 |
Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy CM Kramm, M Chase, U Herrlinger, A Jacobs, PA Pechan, NG Rainov, ... Human gene therapy 8 (17), 2057-2068, 1997 | 192 | 1997 |
Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine … M Aghi, TC Chou, K Suling, XO Breakefield, EA Chiocca Cancer research 59 (16), 3861-3865, 1999 | 180 | 1999 |
Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies M Aghi, TC Cho, EA Chiocca, CM Kramm, XO Breakefield JNCI: Journal of the National Cancer Institute 90 (5), 370-380, 1998 | 178 | 1998 |